Data gathered: February 1
AI Stock Analysis - Sarepta Therapeutics (SRPT)
Analysis generated January 18, 2025. Powered by Chat GPT.
Sarepta Therapeutics, Inc. is a biopharmaceutical company specializing in the development of innovative genetic medicine to treat rare diseases. The company focuses particularly on rare neuromuscular diseases. Sarepta Therapeutics is a leader in gene therapy and has a robust pipeline of potential treatments for Duchenne Muscular Dystrophy (DMD) and other similar conditions.
Stock Alerts - Sarepta Therapeutics (SRPT)
 |
Sarepta Therapeutics | January 13 Price is down by -6.1% in the last 24h. |
|
Sarepta Therapeutics | December 28 AI Score is up by 20.9% in the last couple of days. |
|
Sarepta Therapeutics | December 17 Insider Alert: Wigzell Hans Lennart Rudolf is selling shares |
|
Sarepta Therapeutics | December 17 Employee Rating is up by 2.3% over the last month. |
Alternative Data for Sarepta Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 44 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 27,000 | Sign up | Sign up | Sign up |
| Employee Rating | 88 | Sign up | Sign up | Sign up |
| Google Trends | 14 | Sign up | Sign up | Sign up |
| Patents | 121 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 1,214 | Sign up | Sign up | Sign up |
| Facebook Followers | 9,256 | Sign up | Sign up | Sign up |
| Instagram Followers | 5,359 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 13 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 18,786 | Sign up | Sign up | Sign up |
| Twitter Followers | 5,756 | Sign up | Sign up | Sign up |
| Twitter Mentions | 6 | Sign up | Sign up | Sign up |
| News Mentions | 1 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Lobbying Cost | $83,000 | Sign up | Sign up | Sign up |
| Business Outlook | 87 | Sign up | Sign up | Sign up |
| Linkedin Employees | 1,489 | Sign up | Sign up | Sign up |
About Sarepta Therapeutics
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases.
| Price | $113.72 |
| Target Price | Sign up |
| Volume | 724,640 |
| Market Cap | $10.9B |
| Year Range | $104.54 - $163.85 |
| Dividend Yield | 0% |
| PE Ratio | 73.84 |
| Analyst Rating | 95% buy |
| Industry | Biotechnology |
In the news
 |
Fifth Third Bancorp Boosts Stock Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)February 1 - ETF Daily News |
|
Sarepta Therapeutics’ (SRPT) Sell Rating Reiterated at HC WainwrightFebruary 1 - ETF Daily News |
|
Brokers Set Expectations for SRPT Q4 EarningsFebruary 1 - ETF Daily News |
|
Nisa Investment Advisors LLC Purchases 247 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)January 31 - ETF Daily News |
|
Needham & Company LLC Reiterates Buy Rating for Sarepta Therapeutics (NASDAQ:SRPT)January 28 - ETF Daily News |
 |
Sarepta Therapeutics' Duchenne Gene Therapy Shows Sustained Benefits And Disease Stabilization At Two YearsJanuary 27 - Biztoc.com |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 467M | 129M | 338M | 34M | 40M | 0.340 |
| Q2 '24 | 363M | 139M | 224M | 6.5M | 19M | 0.070 |
| Q1 '24 | 413M | 128M | 286M | 36M | 46M | 0.370 |
| Q4 '23 | 397M | 135M | 262M | 46M | 46M | 0.470 |
| Q3 '23 | 332M | 149M | 183M | -41M | -28M | -0.460 |
Insider Transactions View All
| Wigzell Hans Lennart Rudolf filed to sell 22,840 shares at $124.8. December 16 '24 |
| Boor Kathryn Jean filed to sell 5,880 shares at $125.6. December 6 '24 |
| Estepan Ian Michael filed to sell 33,946 shares at $137.4. September 3 '24 |
| Chambers Michael Andrew filed to buy 284,034 shares at $134.7. August 20 '24 |
| Chambers Michael Andrew filed to buy 260,102 shares at $133.1. August 20 '24 |
Similar companies
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Joshua Gottheimer Democrat |
Aug 21, 23 | Buy | $1K - $15K |
| Joshua Gottheimer Democrat |
Jul 11, 23 | Sell | $1K - $15K |
| Daniel S. Goldman Democrat |
May 19, 23 | Sell | $15K - $50K |
Read more about Sarepta Therapeutics (SRPT) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
What is the Market Cap of Sarepta Therapeutics?
The Market Cap of Sarepta Therapeutics is $10.9B.
What is Sarepta Therapeutics' PE Ratio?
As of today, Sarepta Therapeutics' PE (Price to Earnings) ratio is 73.84.
What is the current stock price of Sarepta Therapeutics?
Currently, the price of one share of Sarepta Therapeutics stock is $113.72.
How can I analyze the SRPT stock price chart for investment decisions?
The SRPT stock price chart above provides a comprehensive visual representation of Sarepta Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Sarepta Therapeutics shares. Our platform offers an up-to-date SRPT stock price chart, along with technical data analysis and alternative data insights.
Does SRPT offer dividends to its shareholders?
As of our latest update, Sarepta Therapeutics (SRPT) does not offer dividends to its shareholders. Investors interested in Sarepta Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Sarepta Therapeutics?
Some of the similar stocks of Sarepta Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.